Supplementary Figure 3 from Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Abstract

<p>Overall survival according to the relative lymphocyte and eosinophil counts in 3 subgroups of patients defined by LDH and the pattern of visceral metastasis. Kaplan Meier curves for OS are presented according to relative lymphocyte count (left), relative eosinophil counts (middle) and the count of favorable pre-treatment values considering both factors (right). In patients 132 patients with LDH-ratio {less than or equal to}2.5 AND no visceral metastasis other than lung (A) OS was significantly longer in patients with RLC {greater than or equal to}17.5% (p=0.003) and in those with 2 vs 0 favorable pretreatment values (p=0.022). In 310 patients with either LDH-ratio {less than or equal to}2.5 OR no visceral metastasis other than lung (B) OS was significantly in all pairwise comparisons of the three biomarker categories (all log rank p<0.001). In 70 patients with LDH-ratio >2.5 AND visceral metastasis other than lung (C) the differences in OS between patients with 2 vs 0 favorable pretreatment factors was not statistically significant (log rank p=0.108).</p>